Alzheimer’s disease (AD) involves early molecular changes beyond amyloid-β (Aβ) and tau, that create heterogeneous disease biology, giving rise to variable disease initiation and highly variable longitudinal trajectories. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.